Autonomic/CV Drugs — MCQs

Q: Which antithyroid drug is safer during the first trimester of pregnancy?

Propylthiouracil. ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred drug for treating hyperthyroidism in the **first trimester of pregnancy** due to a lower risk of teratogenic effects compared to methimazole or carbimazole. - While PTU carries a risk of hepatic toxicity, it is generally favored during early pregnancy to avoid the established teratogenic risks of other thionamides. *Radioactive iodine* - **Radioactive iodine (RAI)** is absolutely contraindicated in pregnancy as it crosses the placenta and can cause permanent **fetal hypothyroidism** or **agenesis of the fetal thyroid gland**. - Its use can lead to the destruction of the fetal thyroid, which is unacceptable given the availability of safer alternatives. *Carbimazole* - **Carbimazole** is converted to methimazole in the body and is associated with a higher risk of **fetal embryopathy** during the first trimester, including aplasia cutis, choanal atresia, and esophageal atresia. - It should generally be avoided in the first trimester if possible, switching to PTU instead. *Methimazole* - **Methimazole** is structurally similar to carbimazole and also carries a significant risk of **teratogenic effects** such as **aplasia cutis**, omphalocele, and choanal atresia when used in the first trimester. - It is often reserved for the second and third trimesters if a thionamide is required, or for patients who cannot tolerate PTU, but ideally avoided in early pregnancy. *Propranolol* - **Propranolol** is a beta-blocker used for symptomatic management of hyperthyroidism (controlling tachycardia, tremor, anxiety) but is not an antithyroid drug and does not treat the underlying hyperthyroidism. - While generally safe in pregnancy, it only provides adjunctive therapy and cannot replace definitive antithyroid treatment.

Q: A patient on SSRI sertraline was also prescribed amitriptyline and subsequently developed serotonin toxicity. What is the likely treatment for serotonin toxicity?

Cyproheptadine. ***Cyproheptadine*** - **Cyproheptadine** is a serotonin antagonist that can help reverse the effects of excessive serotonin in the central nervous system. - It works by blocking **serotonin 5-HT2A receptors**, which are implicated in the pathophysiology of serotonin toxicity. *Flumazenil* - **Flumazenil** is a benzodiazepine receptor antagonist used to reverse the effects of benzodiazepine overdose. - It has no role in the treatment of **serotonin toxicity**, as it does not affect serotonin pathways. *L-Carnitine* - **L-Carnitine** is a mitochondrial co-factor used in fatty acid metabolism, sometimes supplemented for certain metabolic disorders or muscle pain. - It does not have any direct action on **serotonin receptors** or the serotonin system, making it ineffective for serotonin toxicity. *Leucovorin* - **Leucovorin** (folinic acid) is used to counteract the effects of methotrexate toxicity or to enhance the effects of fluorouracil in chemotherapy. - It is not involved in modulating **neurotransmitter levels** or reversing the symptoms of serotonin toxicity. *Naloxone* - **Naloxone** is an opioid receptor antagonist used to reverse opioid overdose. - It has no effect on **serotonin receptors** or serotonergic pathways, making it ineffective for treating serotonin toxicity.

Q: Which of the following drugs is used in opioid maintenance therapy?

Buprenorphine. ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist** used in opioid maintenance therapy to reduce cravings and withdrawal symptoms without producing the full euphoric effects of other opioids. - It is often combined with **naloxone** (as Suboxone) to prevent misuse by injection, as naloxone is only active if injected. - Buprenorphine has a **ceiling effect** for respiratory depression, making it safer than full agonists like methadone. *Naltrexone* - **Naltrexone** is an **opioid antagonist** that blocks opioid receptors, preventing the euphoric effects of opioids and reducing cravings. - While used in opioid use disorder treatment, it is primarily for relapse prevention and not typically for the active maintenance phase where agonist effects are desired. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** primarily used to manage the **autonomic symptoms of opioid withdrawal**, such as anxiety, sweating, and rapid heart rate. - It does not directly act on opioid receptors and is not a primary agent for long-term opioid maintenance therapy. *Disulfiram* - **Disulfiram** is a drug used in the treatment of **alcohol use disorder**, not opioid use disorder. - It works by inhibiting acetaldehyde dehydrogenase, leading to an unpleasant reaction when alcohol is consumed. *Naloxone* - **Naloxone** is an **opioid antagonist** used for **emergency reversal of opioid overdose**, not for maintenance therapy. - It rapidly displaces opioids from receptors and reverses respiratory depression. - While combined with buprenorphine in Suboxone to prevent misuse, naloxone itself is not used for maintenance therapy.

Q: Which of the following growth hormone analogues is not used for the treatment of GH deficiency but is used in the treatment of HIV associated lipodystrophy?

Tesamorelin. ***Tesamorelin*** - **Tesamorelin** is a **growth hormone-releasing hormone (GHRH) analogue** approved specifically for the treatment of **HIV-associated lipodystrophy**. - It works by stimulating the natural production and release of endogenous growth hormone, which helps reduce **visceral adipose tissue** observed in this condition. - **Key distinction:** NOT used for GH deficiency, but specifically for lipodystrophy. *Sermorelin* - **Sermorelin** is also a **GHRH analogue**, but it is primarily used to diagnose and treat **growth hormone deficiency** in children. - It is not approved for lipodystrophy and works by stimulating the pituitary to secrete growth hormone. *Somatropin* - **Somatropin** is the recombinant form of **human growth hormone (GH)** itself, used to treat **growth hormone deficiency** in both children and adults. - While it can affect body composition, its primary indication is not HIV-associated lipodystrophy. *Mecasermin* - **Mecasermin** is recombinant **insulin-like growth factor-1 (IGF-1)** used to treat severe primary IGF-1 deficiency. - It is used for growth failure in children with GH gene deletion or GH receptor defects, not for HIV-associated lipodystrophy. *Pegvisomant* - **Pegvisomant** is a **growth hormone receptor antagonist** used to treat **acromegaly**, a condition caused by excessive growth hormone. - It works by blocking the action of growth hormone at its receptor, directly opposing the therapeutic goal for lipodystrophy.

Q: Caffeine is a widely used stimulant that promotes wakefulness. Which of the following mechanisms is responsible for this effect?

Adenosine antagonism. ***Adenosine antagonism*** - Caffeine acts as a **competitive antagonist** at **adenosine receptors** (primarily A1 and A2A) in the brain. - **Adenosine** is an inhibitory neurotransmitter that promotes drowsiness and reduces neuronal activity; by blocking its receptors, caffeine prevents this sedation and promotes wakefulness. - This is the **primary mechanism** responsible for caffeine's stimulant effects at typical dietary doses. *Increased discharge of norepinephrine from the locus ceruleus* - While increased **norepinephrine** can promote wakefulness, it is not the primary direct mechanism by which caffeine exerts its stimulant effects. - Caffeine may indirectly affect norepinephrine release as a downstream consequence of adenosine receptor blockade, but this is a secondary effect. *Release of histamine* - **Histamine** is indeed a neurotransmitter involved in wakefulness and arousal, but caffeine does not primarily promote wakefulness by directly causing histamine release. - Some antihistamines cause drowsiness by blocking central histamine receptors, but caffeine's mechanism is distinct from the histaminergic system. *Inhibition of phosphodiesterase* - Caffeine does inhibit **phosphodiesterase (PDE)** enzymes, leading to increased intracellular **cAMP** levels. - However, PDE inhibition occurs at significantly **higher concentrations** than those required for adenosine receptor antagonism, making it a less important mechanism for caffeine's typical stimulant effects at common dietary doses (1-3 cups of coffee). *Dopamine reuptake inhibition* - While some CNS stimulants (e.g., **methylphenidate**, **cocaine**) work primarily through dopamine reuptake inhibition, this is **not** caffeine's primary mechanism. - Caffeine may have minor indirect effects on dopamine neurotransmission through its adenosine receptor antagonism, but direct dopamine reuptake inhibition is not a significant mechanism of action.

Autonomic/CV Drugs US Medical PG Practice Questions and MCQs

Question 1: Which antithyroid drug is safer during the first trimester of pregnancy?

A. Radioactive iodine
B. Carbimazole
C. Propylthiouracil (Correct Answer)
D. Methimazole
E. Propranolol

Explanation: ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred drug for treating hyperthyroidism in the **first trimester of pregnancy** due to a lower risk of teratogenic effects compared to methimazole or carbimazole. - While PTU carries a risk of hepatic toxicity, it is generally favored during early pregnancy to avoid the established teratogenic risks of other thionamides. *Radioactive iodine* - **Radioactive iodine (RAI)** is absolutely contraindicated in pregnancy as it crosses the placenta and can cause permanent **fetal hypothyroidism** or **agenesis of the fetal thyroid gland**. - Its use can lead to the destruction of the fetal thyroid, which is unacceptable given the availability of safer alternatives. *Carbimazole* - **Carbimazole** is converted to methimazole in the body and is associated with a higher risk of **fetal embryopathy** during the first trimester, including aplasia cutis, choanal atresia, and esophageal atresia. - It should generally be avoided in the first trimester if possible, switching to PTU instead. *Methimazole* - **Methimazole** is structurally similar to carbimazole and also carries a significant risk of **teratogenic effects** such as **aplasia cutis**, omphalocele, and choanal atresia when used in the first trimester. - It is often reserved for the second and third trimesters if a thionamide is required, or for patients who cannot tolerate PTU, but ideally avoided in early pregnancy. *Propranolol* - **Propranolol** is a beta-blocker used for symptomatic management of hyperthyroidism (controlling tachycardia, tremor, anxiety) but is not an antithyroid drug and does not treat the underlying hyperthyroidism. - While generally safe in pregnancy, it only provides adjunctive therapy and cannot replace definitive antithyroid treatment.

Question 2: A patient on SSRI sertraline was also prescribed amitriptyline and subsequently developed serotonin toxicity. What is the likely treatment for serotonin toxicity?

A. Flumazenil
B. Cyproheptadine (Correct Answer)
C. L-Carnitine
D. Leucovorin
E. Naloxone

Explanation: ***Cyproheptadine*** - **Cyproheptadine** is a serotonin antagonist that can help reverse the effects of excessive serotonin in the central nervous system. - It works by blocking **serotonin 5-HT2A receptors**, which are implicated in the pathophysiology of serotonin toxicity. *Flumazenil* - **Flumazenil** is a benzodiazepine receptor antagonist used to reverse the effects of benzodiazepine overdose. - It has no role in the treatment of **serotonin toxicity**, as it does not affect serotonin pathways. *L-Carnitine* - **L-Carnitine** is a mitochondrial co-factor used in fatty acid metabolism, sometimes supplemented for certain metabolic disorders or muscle pain. - It does not have any direct action on **serotonin receptors** or the serotonin system, making it ineffective for serotonin toxicity. *Leucovorin* - **Leucovorin** (folinic acid) is used to counteract the effects of methotrexate toxicity or to enhance the effects of fluorouracil in chemotherapy. - It is not involved in modulating **neurotransmitter levels** or reversing the symptoms of serotonin toxicity. *Naloxone* - **Naloxone** is an opioid receptor antagonist used to reverse opioid overdose. - It has no effect on **serotonin receptors** or serotonergic pathways, making it ineffective for treating serotonin toxicity.

Question 3: Which of the following drugs is used in opioid maintenance therapy?

A. Naltrexone
B. Clonidine
C. Buprenorphine (Correct Answer)
D. Disulfiram
E. Naloxone

Explanation: ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist** used in opioid maintenance therapy to reduce cravings and withdrawal symptoms without producing the full euphoric effects of other opioids. - It is often combined with **naloxone** (as Suboxone) to prevent misuse by injection, as naloxone is only active if injected. - Buprenorphine has a **ceiling effect** for respiratory depression, making it safer than full agonists like methadone. *Naltrexone* - **Naltrexone** is an **opioid antagonist** that blocks opioid receptors, preventing the euphoric effects of opioids and reducing cravings. - While used in opioid use disorder treatment, it is primarily for relapse prevention and not typically for the active maintenance phase where agonist effects are desired. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** primarily used to manage the **autonomic symptoms of opioid withdrawal**, such as anxiety, sweating, and rapid heart rate. - It does not directly act on opioid receptors and is not a primary agent for long-term opioid maintenance therapy. *Disulfiram* - **Disulfiram** is a drug used in the treatment of **alcohol use disorder**, not opioid use disorder. - It works by inhibiting acetaldehyde dehydrogenase, leading to an unpleasant reaction when alcohol is consumed. *Naloxone* - **Naloxone** is an **opioid antagonist** used for **emergency reversal of opioid overdose**, not for maintenance therapy. - It rapidly displaces opioids from receptors and reverses respiratory depression. - While combined with buprenorphine in Suboxone to prevent misuse, naloxone itself is not used for maintenance therapy.

Question 4: Which of the following growth hormone analogues is not used for the treatment of GH deficiency but is used in the treatment of HIV associated lipodystrophy?

A. Tesamorelin (Correct Answer)
B. Sermorelin
C. Somatropin
D. Pegvisomant
E. Mecasermin

Explanation: ***Tesamorelin*** - **Tesamorelin** is a **growth hormone-releasing hormone (GHRH) analogue** approved specifically for the treatment of **HIV-associated lipodystrophy**. - It works by stimulating the natural production and release of endogenous growth hormone, which helps reduce **visceral adipose tissue** observed in this condition. - **Key distinction:** NOT used for GH deficiency, but specifically for lipodystrophy. *Sermorelin* - **Sermorelin** is also a **GHRH analogue**, but it is primarily used to diagnose and treat **growth hormone deficiency** in children. - It is not approved for lipodystrophy and works by stimulating the pituitary to secrete growth hormone. *Somatropin* - **Somatropin** is the recombinant form of **human growth hormone (GH)** itself, used to treat **growth hormone deficiency** in both children and adults. - While it can affect body composition, its primary indication is not HIV-associated lipodystrophy. *Mecasermin* - **Mecasermin** is recombinant **insulin-like growth factor-1 (IGF-1)** used to treat severe primary IGF-1 deficiency. - It is used for growth failure in children with GH gene deletion or GH receptor defects, not for HIV-associated lipodystrophy. *Pegvisomant* - **Pegvisomant** is a **growth hormone receptor antagonist** used to treat **acromegaly**, a condition caused by excessive growth hormone. - It works by blocking the action of growth hormone at its receptor, directly opposing the therapeutic goal for lipodystrophy.

Question 5: Caffeine is a widely used stimulant that promotes wakefulness. Which of the following mechanisms is responsible for this effect?

A. Adenosine antagonism (Correct Answer)
B. Increased discharge of norepinephrine from the locus ceruleus
C. Release of histamine
D. Inhibition of phosphodiesterase
E. Dopamine reuptake inhibition

Explanation: ***Adenosine antagonism*** - Caffeine acts as a **competitive antagonist** at **adenosine receptors** (primarily A1 and A2A) in the brain. - **Adenosine** is an inhibitory neurotransmitter that promotes drowsiness and reduces neuronal activity; by blocking its receptors, caffeine prevents this sedation and promotes wakefulness. - This is the **primary mechanism** responsible for caffeine's stimulant effects at typical dietary doses. *Increased discharge of norepinephrine from the locus ceruleus* - While increased **norepinephrine** can promote wakefulness, it is not the primary direct mechanism by which caffeine exerts its stimulant effects. - Caffeine may indirectly affect norepinephrine release as a downstream consequence of adenosine receptor blockade, but this is a secondary effect. *Release of histamine* - **Histamine** is indeed a neurotransmitter involved in wakefulness and arousal, but caffeine does not primarily promote wakefulness by directly causing histamine release. - Some antihistamines cause drowsiness by blocking central histamine receptors, but caffeine's mechanism is distinct from the histaminergic system. *Inhibition of phosphodiesterase* - Caffeine does inhibit **phosphodiesterase (PDE)** enzymes, leading to increased intracellular **cAMP** levels. - However, PDE inhibition occurs at significantly **higher concentrations** than those required for adenosine receptor antagonism, making it a less important mechanism for caffeine's typical stimulant effects at common dietary doses (1-3 cups of coffee). *Dopamine reuptake inhibition* - While some CNS stimulants (e.g., **methylphenidate**, **cocaine**) work primarily through dopamine reuptake inhibition, this is **not** caffeine's primary mechanism. - Caffeine may have minor indirect effects on dopamine neurotransmission through its adenosine receptor antagonism, but direct dopamine reuptake inhibition is not a significant mechanism of action.

Practice by Chapter

Antiarrhythmic classification and mechanisms

Practice Questions

Class I antiarrhythmics (sodium channel blockers)

Practice Questions

Class II antiarrhythmics (beta blockers)

Practice Questions

Class III antiarrhythmics (potassium channel blockers)

Practice Questions

Class IV antiarrhythmics (calcium channel blockers)

Practice Questions

Other antiarrhythmic agents

Practice Questions

Antianginal drugs

Practice Questions

Positive inotropic agents

Practice Questions

Phosphodiesterase inhibitors

Practice Questions

Cardiac glycosides

Practice Questions

Vasopressors and inotropes

Practice Questions

Pulmonary hypertension therapies

Practice Questions

Peripheral vascular disease therapies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free